SCHEMBL24460474

SCHEMBL24460474

CC1CC(C(=N)N)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6278869 0.81
SCHEMBL6285060 0.78 NOS2 (0.61)
SCHEMBL8948266 0.75
SCHEMBL14942478 0.74 NOS2 (0.72)
SCHEMBL14082057 0.74 NOS2 (0.72)
SCHEMBL25605217 0.73
SCHEMBL12332568 0.71
SCHEMBL24516568 0.71
SCHEMBL4196054 0.71
SCHEMBL25783360 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188040-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS VIVIDION THERAPEUTICS INC 2025-06-12 US disclosed
EP-4551555-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS Vividion Therapeutics, Inc. (US) 2025-05-14 EP disclosed
CN-119677716-A Pharmaceutical compositions comprising WRN helicase inhibitors 维维迪恩医疗公司 2025-03-21 CN disclosed
US-12187685-B2 Pharmaceutical compositions comprising WRN helicase inhibitors VIVIDION THERAPEUTICS, INC. 2025-01-07 US disclosed
US-20240140915-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS VIVIDION THERAPEUTICS, INC. 2024-05-02 US disclosed
US-20240067612-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS VIVIDION THERAPEUTICS, INC. 2024-02-29 US disclosed
WO-2024010782-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS VIVIDION THERAPEUTICS, INC. (US) 2024-01-11 WO disclosed
WO-2023066292-A1 TRICYCLIC BORONIC ACID DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海济煜医药科技有限公司 2023-04-27 WO disclosed
WO-2022109580-A1 INHIBITION OF TYK2 DEPENDENT SIGNALING PATHWAYS JANSSEN PHARMACEUTICA NV (BE) 2022-05-27 WO disclosed